ArticleInternational journal of clinical oncology2026
Exploring plasma cell-free RNA biomarkers for predicting immune checkpoint inhibitor efficacy in gastric cancer: a translational sub-study of the KSCC VOYAGER phase II trial.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICI) are used to treat unresectable advanced or recurrent gastric cancer; however, reliable predictive biomarkers remain limited. This study aimed to identify biomarkers for predicting ICI efficacy using two independent cohorts.
methodsPlasma-derived cell-free RNA (cfRNA) transcriptome analysis was performed on pretreatment plasma samples from 34 patients in the VOYAGER phase II trial of the early induction of nivolumab monotherapy as third line or later. Candidate genes were identified using differentially expressed gene analyses based on three indicators: disease progression during treatment, best response, and progression-free survival ≥ 6 months. These candidates were validated by immunohistochemistry in tumor tissue from an independent cohort of 64 patients treated with nivolumab. Additional immune analyses were conducted using The Cancer Genome Atlas and CIBERSORT.
resultsReceptor-interacting serine/threonine-protein kinase 4 (RIPK4) was consistently upregulated in non-responders across all analyses. In the validation cohort, RIPK4-positive patients receiving nivolumab as first-line therapy exhibited significantly shorter progression-free survival (hazard ratio 2.62, 95% confidence interval 1.08-6.37). RIPK4 expression was also associated with a lower disease control rate (30% vs. 68%, p = 0.005). TCGA-based analyses showed that tumors with high RIPK4 exhibited significantly reduced PDCD1 and CD8A expression alongside a lower fraction of M2 macrophages and CD8
conclusionsElevated RIPK4 expression in plasma-derived cfRNA and tumor tissue was associated with a poor response to nivolumab, suggesting that RIPK4 may serve as a biomarker of ICI efficacy in gastric cancer. Further studies are warranted to validate its clinical utility.
Indexed as
Identifiers
42262687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.